**Equity Swap Contract**

This contract is an equity swap agreement between Party A and Party B, entered into on September 24, 2001. The trade is identified by the global reference "33f59567" and external reference "party1".

**Trade Details**

* Trade Date: September 24, 2001
* Trade Identifier: "6234" with scheme "http://www.partyA.com/eqs-trade-id"
* Global Key: "9593cc32"
* Trade Lot: The contract is for a single trade lot.

**Counterparties**

* Party A: Identified by the global reference "33f59567" and external reference "party1"
* Party B: Identified by the global reference "33f59568" and external reference "party2"

**Contractual Terms**

* Product: Equity Swap
* Contractual Product: Equity:Swap:PriceReturnBasicPerformance:SingleName
* Product Taxonomy: Source "Other" and "ISDA"
* Economic Terms:
	+ Effective Date: Three business days after the trade date, with a day type of "ExchangeBusiness"
	+ Termination Date: The date of the final equity payment date, with a day type of "CurrencyBusiness"
	+ Payout:
		- Interest Rate Payout: Party A pays Party B the difference between the fixed rate and the floating rate, with a day count fraction of ACT/360
		- Performance Payout: Party B pays Party A the difference between the performance of the underlying security and the fixed rate, with a settlement type of "Cash" and a settlement currency of USD
	+ Calculation Agent: Party A is the calculation agent
* Trade Lot:
	+ Price Quantity: The contract is for 760,400 shares of the underlying security, with a price of 37.44 USD per share
	+ Observable: The underlying security is identified by the product identifier "SHPGY.O" and "Shire Pharmaceuticals Group - American Depositary Receipts"
	+ Settlement Terms: The settlement type is "Cash"
* Return Terms:
	+ Price Return Terms: The return type is "Total"
	+ Dividend Return Terms: The dividend payout ratio is 1, with a dividend reinvestment of false and a dividend entitlement of "ExDate"
* Underlier:
	+ Security: The underlying security is an equity security
	+ Product Identifier: The product identifier is "SHPGY.O" and "Shire Pharmaceuticals Group - American Depositary Receipts"
* Valuation Dates:
	+ Interim Valuation Date: The valuation dates are the 12th of October, November, December, January, February, March, April, May, June, July, and August, with a valuation time type of "Close"
	+ Final Valuation Date: The final valuation date is the 24th of September, 2002, with a valuation time type of "HedgeExecution"

**Contractual Party**

* Party A: Identified by the global reference "33f59567" and external reference "party1"
* Party B: Identified by the global reference "33f59568" and external reference "party2"

**Documentation**

* The contract is governed by the ISDA Master Agreement and the Confirmation.
* The governing law is English.
* The documentation is in the form of a Confirmation.

**Representations**

* Each party represents that it is acting for its own account and has made its own independent decisions to enter into the contract.
* Each party represents that it is capable of assessing the merits and risks of the contract and understands and accepts the terms, conditions, and risks of the contract.
* Each party represents that the other party is not acting as a fiduciary for or an adviser to it in respect of the contract.

**Risk Disclosure**

* The contract carries significant risks, including but not limited to, foreign exchange risk, price risk, liquidity risk, and credit risk.
* Each party should consult its own financial, legal, accounting, and tax advisors about the risks associated with the contract.

**Scenario Analysis**

* The contract is subject to a scenario analysis, which assumes various levels of USD SOFR-COMPOUND and shows the resultant cash flow gain/loss to Party B.

**MTM Sensitivity Analysis**

* The contract is subject to an MTM sensitivity analysis, which shows the changes in the MTM due to parallel shifts in the USD SOFR-COMPOUND curve.

**Level of Pricing Variables and Impact of Variables on Pricing**

* The contract is subject to a level of pricing variables and impact of variables on pricing analysis, which shows the primary market variables used for determining the price of the contract and their directional impact.

**Representations and Warranties**

* Each party represents and warrants that it has the power to enter into the contract and to deliver any document relating to the contract and to perform its obligations under the contract.

**Risk Information**

* The contract carries issuer risk, liquidity risk, and credit risk.
* Investors should be prepared to hold the contract until maturity, if not called or terminated early by the issuer.

**Disclaimer**

* The contract is provided for discussion and/or information purposes only and does not constitute an offer or solicitation of an offer to enter into a securities or other transaction.
* The information contained in this document has been internally developed or taken from trade and statistical services and other sources which we deem reliable, but no warranty is made that such information is accurate or complete and it should not be relied upon as such.